UCLA Translational Researchers Report New Combination Therapy That Increases Progression-Free Survival in Hormone-Receptor

 UCLA Translational Researchers Report New Combination Therapy That Increases
Progression-Free Survival in Hormone-Receptor-Positive Breast Cancer Patients

PR Newswire

LOS ANGELES, Dec. 5, 2012

LOS ANGELES, Dec.5, 2012 /PRNewswire/ --Researchers from the Revlon/UCLA
Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center
(JCCC) reported an encouraging increase in progression-free survival (PFS, the
length of time a patient is on treatment without tumor growth) for patients
with breast cancer that was estrogen receptor positive (ER+), HER2-negative
who were given a combination of the standard anti-estrogen treatment,
letrozole, and a new experimental drug called PD 0332991. This new clinical
study using PD 0332991, which was sponsored by Pfizer Inc., compared the
combination to letrozole alone in ER+ breast cancer patients.

Reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium in San
Antonio, TX on Dec. 5, 2012, the two-part Phase II clinical trial was led by
Dr. Richard S. Finn, Associate Professor of Medicine at UCLA and JCCC member.
The clinical study built on preclinical work from the Translational Oncology
Research Laboratory (TORL) directed by Dr. Dennis Slamon, Professor of
Medicine at JCCC and director of the Revlon/UCLA Women's Cancer Research
Program.

In part 1 of the study 66 patients were enrolled. Preliminary results showed
significant improvement in median PFS of the patients who were given the new
drug combination. Ninety-nine more patients were enrolled in part 2 of the
study, which allowed only for patients whose tumors revealed selected
biomarkers: CCND1 amplification and p16 loss. Retrospective analysis from part
I suggested clinical benefit from PD-332991 regardless of status of the
biomarkers. All other demographic features for the patients in the study were
similar, so for final trial analysis the results of the two parts of the study
were combined for the San Antonio Breast Cancer Symposium presentation.

With the results from the two parts added together, data analysis showed that
the median PFS of patients on the combination arm was 26.1 months compared to
7.5 months among those given letrozole alone. Of patients with measurable
disease, 45% of the women given the combination had confirmed responses,
compared to 31% with letrozole alone, and the clinical benefit rates (tumor
shrinkage and/or stable disease for a minimum of 6 months) were 70% and 44%,
respectively.

"This drug combination demonstrated a dramatic and clinically meaningful
effect on PFS in women with ER positive breast cancer," Finn said, "These
results confirm the preclinical work we began at TORL."

Finn and colleagues published their initial preclinical data in 2009, which
showed that PD 0332991 blocked important proteins in cancer cells called
cyclin D kinases 4 and 6 (CDK 4/6), thus blocked the growth of ER+ and
HER2-amplified cancer cells in the laboratory.

With the goal of identifying important targets of cancer therapy in the
laboratory and promptly developing them into patient treatments using the
translational paradigm, the investigators and Pfizer then conducted a Phase I
clinical trial in which the safety of the drug was tested. Those results
prompted the Phase II trial that compared the combination of PD 0332991 and
letrozole to the standard treatment for these patients of letrozole alone.
Critical to the clinical studies was the synergistic interactions observed in
the laboratory between PD 0332991 and standard breast cancer drugs tamoxifen
and trastuzumab, which are used in ER+ and HER2+ breast cancers, respectively.

"The results of this Phase II study validate the TORL approach," said Slamon,
who is the senior author on the study. He further stated that "by identifying
these targets for treatment, we move forward with personalized oncology that
greatly improves the chances for this group of patients. These results are as
exciting as the initial results we saw for trastuzumab (Herceptin) in HER2+
breast cancers but represent a new approach for a different and larger subset
of breast cancers, i.e. those that are ER+."

The laboratory research was supported primarily through the Revlon/UCLA
Women's Cancer Research Program and longtime philanthropic support from Ronald
O. Perelman. Additional resources were provided by a grant from the Department
of Defense Innovator Award W81XWH-05-1-0395 and the Noreen Fraser Foundation.
The clinical trial itself was sponsored and supported entirely by Pfizer, Inc.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and
clinicians engaged in disease research, prevention, detection, control,
treatment and education. One of the nation's largest comprehensive cancer
centers, the Jonsson center is dedicated to promoting research and translating
basic science into leading-edge clinical studies. In July 2012, the Jonsson
Cancer Center was once again named among the nation's top 10 cancer centers by
U.S. News & World Report, a ranking it has held for 12 of the last 13 years.
For more information on the Jonsson Cancer Center, visit our website at
http://www.cancer.ucla.edu.

SOURCE UCLA's Jonsson Comprehensive Cancer Center

Website: http://www.cancer.ucla.edu
Contact: Shaun Mason, +1-310-206-2805
 
Press spacebar to pause and continue. Press esc to stop.